Once again, fueled by booming sales of their GLP-1 products, Eli Lilly and Novo Nordisk were the top performers in the biopharma industry in the second quarter. | The momentum the biopharma industry showed in the first quarter of 2024 continued into the second quarter as 21 of the industry’s top 25 companies achieved year-over-year revenue increases. Once again, the dominant players were the sellers of GLP-1 diabetes and obesity drugs Eli Lilly and Novo Nordisk, which saw revenue boosts of 36% and 27%, respectively.
Source: 21 of biopharma industry’s top 25 saw revenue increases in Q2 | Fierce Pharma
